Immunologic Factor
muromonab-CD3
[ myoo-roh-moh-nab ... ]
Effect:
Decreased Cytokine Activity; Decreased Lymphocyte Cell Production; Increased T Lymphocyte Destruction
May Treat:
Graft vs Host Disease
Definitions related to muromonab-cd3:
-
A murine IgG2a monoclonal antibody with immunosuppressive activity. Muromonab-CD3 binds to and inhibits CD3 on the surface of circulating T-lymphocytes; binding of muromonab-CD3 to CD3-positive T cells results in an early activation of this T cell subset, followed by cytokine release, and subsequently inhibition of T cell functions. This agent may cause the opsonization and elimination of CD3-positive T cells from the circulation by mononuclear phagocytes in the liver and spleen. CD3 is part of the functional T cell receptor (TCR) complex, which is necessary for antigen recognition by T cells, and is required for signal transduction.NCI ThesaurusU.S. National Cancer Institute, 2021
-
Anti-CD3 monoclonal antibody that exerts immunosuppressive effects by inducing peripheral T-cell depletion and modulation of the T-cell receptor complex (CD3/Ti).NLM Medical Subject HeadingsU.S. National Library of Medicine, 2021
-
(muromonab-cd3 monoclonal antibody) A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.NCI Dictionary of Cancer TermsU.S. National Cancer Institute, 2021
Return to OpenMD Medical Dictionary
> M
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.